← Back to Search

Durvalumab for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Catherine Shu, MD
Research Sponsored by Catherine Shu
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

Summary

This trial tests if it is safe and possible to use two immunotherapy drugs, durvalumab and tremelimumab, for lung cancer patients who have finished standard treatment but still have cancer DNA in their blood. The goal is to see if these drugs can help the immune system fight any remaining cancer cells. Durvalumab and tremelimumab are immune checkpoint inhibitors that have been considered for the treatment of different types of cancers, including lung cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of evaluable patients enrolled
Secondary study objectives
Adverse events rate
Disease free survival
Overall survival
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: durvalumab+ tremelimumabExperimental Treatment2 Interventions
durvalumab will be administered Q4weeks and tremelimumab will be administered Q8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Durvalumab
2017
Completed Phase 2
~3840
Tremelimumab
2017
Completed Phase 2
~3130

Find a Location

Who is running the clinical trial?

Catherine ShuLead Sponsor
1 Previous Clinical Trials
2 Total Patients Enrolled
Catherine Shu, MDPrincipal InvestigatorColumbia University
2 Previous Clinical Trials
41 Total Patients Enrolled
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top